Compare Gilead Sciences, Inc. (GILD) vs Exxon Mobil Corporation (XOM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Exxon Mobil Corporation — how do they compare? Gilead Sciences, Inc. trades at $133.51 (market cap $163.51B), while Exxon Mobil Corporation trades at $146.18 (market cap $598.99B). The key difference: Exxon Mobil Corporation is far larger — about 3.7× Gilead Sciences, Inc.'s market cap, and Exxon Mobil Corporation pays the higher dividend (2.85%). Which is the better fit depends on your goals.
| GILD | XOM | |
|---|---|---|
Market Cap | $163.51B | $598.99B |
Sector | Health | Energy |
52-Week High | $155.80 | $171.52 |
52-Week Low | $108.22 | $105.83 |
Enterprise Value | $178.05B | $638.21B |
Dividend Yield | 2.49% | 2.85% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
ExxonMobil (XOM) trades at $145.09, up 0.4% on the day, with a bullish technical signal from moving averages despite some overbought RSI readings. The company has beaten earnings estimates for three consecutive quarters, though revenue and net income have declined from 2022 peaks. Recent news highlights Exxon's Permian Basin advantages and potential oil price spikes to $160, while the company relocated its legal headquarters to Texas for business-friendly policies.
XOM offers value with a consensus price target of $169.30 (16.7% upside) and a 40.74% analyst buy rating, supported by a strong balance sheet and dividend. Risks include declining profitability margins, volatile oil prices, and geopolitical tensions affecting energy markets. The stock's investment case hinges on execution in low-breakeven assets and capital discipline amid uncertain macro conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Exxon Mobil Corporation
Exxon Mobil Corporation operates petroleum and petro chemicals businesses. The Company provides operations include exploration and production of oil and gas, electric power generation, and coal and minerals operations. Exxon Mobil also manufactures and markets fuels, lubricants, and chemicals. Exxon Mobil serves customers worldwide.
Read more on XOM →
